Renal Cancer - Results from #1340

The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. September 27, 2022

Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma As First-line Therapy: A Single Institution 13-year Experience. September 26, 2022

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. September 26, 2022

The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer. September 23, 2022

Recurrence pattern in localized RCC: results from a European multicenter database (RECUR). September 23, 2022

The Predictive Value of Three Variables in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Based Combination Therapies in Randomized Clinical Trials: A Systematic Review and Meta-Analysis. September 22, 2022

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. September 22, 2022

How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? September 22, 2022

SHMT2 regulates serine metabolism to promote the progression and immunosuppression of papillary renal cell carcinoma. September 21, 2022

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. September 21, 2022

Predicting Oncologic Outcomes in Small Renal Tumors. September 20, 2022

The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. September 20, 2022

Machine learning-based prediction model for late recurrence after surgery in patients with renal cell carcinoma. September 19, 2022

Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. September 19, 2022

Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. September 16, 2022

Epidemiology of Renal Cell Carcinoma: 2022 Update. September 16, 2022

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. September 15, 2022

Management of renal cell carcinoma in transplant kidney: a systematic review and meta-analysis. September 15, 2022

Screening of Differentially Expressed Iron Death-Related Genes and the Construction of Prognosis Model in Patients with Renal Clear Cell Carcinoma. September 14, 2022

Immunohistochemical Expression of CD44, MMP-2, MMP-9, and Ki-67 as the Prognostic Markers in Non-Clear Cell Renal Cell Carcinomas-A Prospective Cohort Study. September 14, 2022

Page 68 of 458